Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Traws Pharma Inc TRAW

Healthcare
Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The Company is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a... see more

Recent & Breaking News (NDAQ:TRAW)

Onconova Therapeutics, Inc. Announces Closing of $11.0 Million Public Offering

GlobeNewswire November 25, 2019

Onconova Therapeutics, Inc. Announces $11.0 Million Public Offering

GlobeNewswire November 21, 2019

Onconova Therapeutics Announces Exclusive License Agreement with Knight Therapeutics for Rigosertib in Canada

GlobeNewswire November 21, 2019

Onconova Announces Five Presentations on Rigosertib in Myelodysplastic Syndromes (MDS) at the ASH 2019 Annual Meeting & Exposition

GlobeNewswire November 7, 2019

Onconova Affirms Planned Completion of Pivotal Phase 3 INSPIRE Study of Rigosertib in Myelodysplastic Syndromes by 1H20 And Provides Research & Development Update

GlobeNewswire October 24, 2019

Onconova Therapeutics, Inc. Announces $3.4 Million Registered Direct Offering of Common Stock

GlobeNewswire September 23, 2019

Onconova Therapeutics Announces Termination of Proposed Public Offering

GlobeNewswire September 18, 2019

Onconova Therapeutics Announces Presentation on Rigosertib at the RAS-Targeted Drug Discovery Summit

GlobeNewswire September 16, 2019

Onconova Therapeutics, Inc. Reports Business Highlights and Second Quarter 2019 Financial Results

GlobeNewswire August 14, 2019

Onconova Therapeutics and Mission Bio Partner to Advance Precision Oncology Clinical Trials Employing Single-Cell Genomics

GlobeNewswire August 12, 2019

Onconova Therapeutics, Inc. to Provide Corporate Update and Second Quarter 2019 Financial Results

GlobeNewswire August 7, 2019

Onconova Therapeutics Announces Presentations at the 24th Congress of the European Hematology Association

GlobeNewswire June 10, 2019

Onconova Therapeutics Announces Presentations at Three Upcoming Conferences

GlobeNewswire May 28, 2019

Onconova Therapeutics, Inc. Reports Business Highlights and First Quarter 2019 Financial Results

GlobeNewswire May 14, 2019

Onconova Therapeutics Announces License Agreement with HanX Biopharmaceuticals to Develop and Commercialize Rigosertib in Greater China

GlobeNewswire May 13, 2019

Onconova Therapeutics, Inc. to Provide Corporate Update and First Quarter 2019 Financial Results

GlobeNewswire May 7, 2019

Onconova Therapeutics Announces Presentations at the 15th International Symposium on Myelodysplastic Syndromes (MDS 2019) in Copenhagen, Denmark

GlobeNewswire May 6, 2019

Onconova Therapeutics to Present Update at the 2019 HCW Global Life Sciences Conference in London, April 7-9

GlobeNewswire April 2, 2019

The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs

Benzinga.com  March 26, 2019

Onconova Therapeutics, Inc. Reports Business Highlights and Full Year 2018 Financial Results

GlobeNewswire March 26, 2019